[Study on adoptive immunotherapy for experimental brain tumor].
Adoptive immunotherapy for the experimental murine brain tumor has been investigated using LAK cells generated in vitro from normal spleen cells with IL-2 and immune spleen cells from Fischer rats immunized against syngenic gliosarcoma, T9. IL-2 inhibitor(s) activity in serum was also studied. LAK cells and immune spleen cells were adoptively transferred to the rats intravenously or intratumorally on the 7th day after the inoculation of T9 into the right basal ganglia. Then the survival rate and necrotic foci were compared between the groups treated with those cells and the control. The survival rate of the groups treated with LAK cells was significantly higher than that of the control (administrated intravenously; P less than 0.01, administrated intratumorally; P less than 0.05). But the treatment with immune spleen cells was not effective. The incidence and area of necrotic foci in the tumors treated with LAK cells were greater than those of the others. Microautoradiography was also performed using 3H-TdR labeled LAK cells, which were administrated intravenously to the model. It was revealed that LAK cells accumulated in lung shortly after the administration, then in liver and spleen, especially in the white pulp. IL-2 inhibitor activity of the sera from the tumor-bearers was greater than that of normal rats, while it was depressed markedly by cyclophosphamide (60 mg/kg i.p.). In conclusion, the adoptive transfer of LAK cells can be one of the effective and attractive treatments of the brain tumor. In order to make immunotherapy more effective it should be necessary to clarify the nature of IL-2 inhibitor(s).